Navigation Links
Pieris Progresses Development of its Proprietary Biotherapeutics,Platform: Successful Demonstration of Dual Targeting With,Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin(R) technology has successfully demonstrated dual targeting potential.

Commenting on this development, Dr Andreas Hohlbaum, Director of Science and Preclinical Development of Pieris said: "As Pieris continues to validate the therapeutic application of its technologies, dual targeting is viewed as a major step forward. Combining the benefits of bivalent, avid binding of disease targets with the ability to modulate two targets at once shows the clear development potential of the Duocalin(R) technology to treat multi-factorial diseases".

Using individual monomeric Anticalins(R) selected to have picomolar binding affinity to distinct determinants on two defined clinically validated targets, Pieris has constructed Duocalins(R) as monomeric, bivalent binding proteins that retain target specificity and affinity regardless of the structural orientation of their binding domains. Furthermore, the high intrinsic stability of Duocalins(R) is comparable to monomeric Anticalins(R), offering flexible formulation and delivery potential for Duocalin(R)-based drug candidates.

Despite the low molecular weight of monomeric Anticalins(R) relative to antibodies, their core scaffold provides a highly selective binding site with high structural plasticity and an extensive binding surface comparable to that achieved with antibodies. The adaptability of the Anticalin(R) scaffold has already allowed Pieris to develop therapeutic and diagnostic product candidates with custom designed functionality. Duocalins(R) allow multiple targets to be bound and modulated through a single molecule, which is particularly advantageous in diseases known to involve more than a single causative factor. Moreover,
'"/>




Page: 1 2 3

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies
3. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
4. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
7. CuraGen Presents Update on Clinical Development Program for Belinostat
8. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
11. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
Post Your Comments:
(Date:6/19/2013)... CARLSBAD, Calif. , June 19, 2013 /PRNewswire/ ... ) today announces a licensing agreement granting Suzhou ... develop and manufacture siRNA therapeutics in ... technology.  Ribo will formulate proprietary siRNA molecules in ... platform designed to address human diseases with high ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... management solutions, introduced the next-generation of its ... which allows health plans to provide their employer ... populations, health factors, medical and prescription drug claims, ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
(Date:6/19/2013)... 2013 Specialty Coating Systems ... von SCS microRESIST™, einer antimikrobiellen Parylene-Technologie, ... mit Parylene gelungen ist. SCS microRESIST ... mit antimikrobiellen Eigenschaften und erlaubt damit ... beschichteten medizinischen Geräten. (Logo: ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... winner Gloria Gaynor -- whose hit songs have captivated the ... Orlando@50+ National Event & Expo to raise awareness ... potentially debilitating condition. This high profile event, with an estimated ... at the Orange County Convention Center in Orlando, FL. ...
... Biotechnology, Inc. (Pink Sheets: ACEL ) ... by the National Institute of Allergy and Infectious ... our lead compounds outperformed market leader Roche,s drug ... (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, ...
Cached Medicine Technology:Gloria Gaynor to Appear at AARP's Orlando@50+ National Event & Expo 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
(Date:6/19/2013)... A University of Iowa study reveals significant disparities ... for completing substance abuse treatment programs. Moreover, these ... , "Our findings suggest that for most states ... professor of psychiatry and biostatistics. "There are strong ... able to complete substance abuse treatment programs successfully, ...
(Date:6/19/2013)... percent of Americans are on at least one ... Mayo Clinic researchers say. Antibiotics, antidepressants and painkilling ... Twenty percent of patients are on five or ... online in the journal Mayo Clinic Proceedings ... of Dr. Jennifer St. Sauver talking about the ...
(Date:6/19/2013)... pharmaceutical companies, along with the Japanese government and ... commitment to bolster Japan,s contribution to global health ... Fund), at a press conference held as a ... on African Development (TICAD V). , Representatives from ... of Health, Labour and Welfare, the Ministry of ...
(Date:6/19/2013)... PREFERRED Therapy Providers, Inc. (PREFERRED) has ... to offer a new Medicare Advantage Plan for PREFERRED’s ... and Mohave, Arizona counties. The agreement takes effect in ... 1, 2013 and Maricopa and Pima counties will become ... parent company of WellCare of Arizona has Medicare Advantage ...
(Date:6/19/2013)... June 19, 2013 Guests at the Residence ... and wise even if they don’t go to bed or ... some early thought. , Crafty travelers will ... take advantage of the pet-friendly Scottsdale Paradise Valley hotel’s Book ... With at least 14 days advance notice, guests can enjoy ...
Breaking Medicine News(10 mins):Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... , SATURDAY, Nov. 19 (HealthDay News) -- Eating certain ... white after you,ve used an at-home whitening kit or ... individuals who have had good results with either dentist-directed ... to keep the teeth white after bleaching," Dr. Raymond ...
... 18 (HealthDay News) -- A new study finds that many ... seat belt when they ride in cars -- a practice ... at a 2007 National Highway Traffic Safety Administration survey of ... their 4- to 9-year-old passengers use seat belts and more ...
... - IBM,s Watson computing system broke new ground earlier this ... Jeopardy! game show. Now, The Scripps Research Institute is hoping ... health with part of the prize money from that tournament: ... the public,s help. To that end, Scripps Research ...
... , FRIDAY, Nov. 18 (HealthDay News) -- Those in the ... U.S. government health experts now encourage Americans to ... new system assigns no points to nearly all fruits and ... what,s the big deal? Why is it so important to ...
... Nov. 18 (HealthDay News) -- Hispanics are the focus of ... says the American Podiatric Medical Association (APMA). Hispanics are ... diabetes, which can result in foot ulcers and lower limb ... lack of exercise and genetics, risk factors that are especially ...
... -- Researchers at Wake Forest Baptist Medical Center and ... up for a research project aimed at advancing the ... (PTSD) and traumatic brain injury (TBI). "PTSD ... coming home from Iraq and Afghanistan," said Dwayne W. ...
Cached Medicine News:Health News:Watch What You Eat After Teeth-Whitening, Expert Says 2Health News:Ill-Fitting Children's Seat Belts Common in U.S., Study Finds 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 3Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 2Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 3Health News:For Nutritional Punch, You Can't Beat Plant-Based Foods 4Health News:Hope on the horizon for patients with post-traumatic stress disorder 2Health News:Hope on the horizon for patients with post-traumatic stress disorder 3
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
10 L, Bulk Recommended for 5 and 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: